Testing an antiplatelet medication to prevent stroke recurrence after clot-busting therapy

This trial is testing whether tirofiban, an antiplatelet medication, can safely prevent blood clots from reforming after patients receive emergency clot-busting treatment (tenecteplase) for acute ischemic stroke. After the clot-busting drug dissolves the blockage in the brain, the blood clot sometimes reforms in 14-34% of patients. This study wants to see if giving this medication early can reduce that risk and help patients recover better.

Even after successful emergency clot-busting therapy, some stroke patients experience the clot reforming, which can cause their condition to worsen. Early antiplatelet therapy might prevent this dangerous complication and improve how well patients recover.